By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.

The partners did not provide details on the screening and optimization platform.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.